DLBCL   

Given the results of ZUMA-7, TRANSFORM, and BELINDA - how does this inform your current practice? What are the currently approved indications for CAR-...

Can grade 1 toxicities (e.g. CRS) be monitored safely as an outpatient?

Which patients, if any, do you screen with ctDNA-based assays? What management strategies do you discuss with patients who are MRD-positive?

At the time of initial diagnosis, there was no clear CNS involvement. When it became clinically apparent disease was refractory to EPOCH, there was CS...

In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...

Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...

When is this discussed? What are the common/less common toxicities you advise patients on? Are there best practices for coordination with referring on...